Restenosis
Cross-source consensus on Restenosis from 1 sources and 3 claims.
1 sources · 3 claims
Benefits
Risks & contraindications
Evidence quality
Highlighted claims
- More than 40% of patients develop restenosis after PCI, leading to recurrent MI, angina, and the need for repeat interventions. — Adjunctive Tongxinluo capsule for patients with acute coronary syndromes undergoing percutaneous coronary intervention: a GRADE-assessed systematic review and meta-analysis of randomised controlled trials
- TXL plus standard Western therapy produced a statistically significant 70% relative risk reduction in restenosis compared to Western therapy alone, with an NNT of 18. — Adjunctive Tongxinluo capsule for patients with acute coronary syndromes undergoing percutaneous coronary intervention: a GRADE-assessed systematic review and meta-analysis of randomised controlled trials
- Sensitivity analysis using a fixed-effect model confirmed the robustness of the restenosis reduction finding. — Adjunctive Tongxinluo capsule for patients with acute coronary syndromes undergoing percutaneous coronary intervention: a GRADE-assessed systematic review and meta-analysis of randomised controlled trials